Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Basic Research in Cardiology
Metadata
Title
Erythropoietin protects the myocardium against reperfusion injury in vitro and in vivo
Authors
A. J. Bullard
P. Govewalla
D. M. Yellon
Publication date
01-09-2005
Publisher
Steinkopff-Verlag
Published in
Basic Research in Cardiology / Issue 5/2005
Print ISSN: 0300-8428
Electronic ISSN: 1435-1803
DOI
https://doi.org/10.1007/s00395-005-0537-4

Other articles of this Issue 5/2005

Basic Research in Cardiology 5/2005 Go to the issue

ORIGINAL CONTRIBUTION

Adrenomedullin limits reperfusion injury in experimental myocardial infarction

ORIGINAL CONTRIBUTION

Intracoronary formation and retention of micro aggregates of leukocytes and platelets contribute to postischemic myocardial dysfunction

ORIGINAL CONTRIBUTION

Regional differences in the dynamics of refractoriness in intact and hypertrophied in situ canine hearts

ORIGINAL CONTRIBUTION

Thyroid hormone receptors α1 and β1 are downregulated in the post-infarcted rat heart: consequences on the response to ischaemia-reperfusion

ORIGINAL CONTRIBUTION

Remote postconditioning

ORIGINAL CONTRIBUTION

Relevance of the NOS3 T–786C and G894T variants for cholinergic and adrenergic coronary vasomotor responses in man

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits